Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07

Current Colorectal Cancer Reports

Volumn 5, Issue 3, 2009, Pages 166-170

  Boni, Corrado ^a   André, Thierry ^a   Banzi, Maria Chiara ^a   Hickish, Tamas ^a   Tabernero, Josep ^a   Clingan, Philip ^a   Chibaudel, Benoist ^a   De Gramont, Aimery ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CLINICAL PROTOCOL; COLON CANCER; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM INJURY; EMBOLISM; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE INJURY; NEUTROPENIA; PERIPHERAL NEUROPATHY; REVIEW; STUDY DESIGN; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

EID: 77954380408     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-009-0024-7     Document Type: Review

References (24)

1. Moertel CG, Fleming TR, Macdonald JS, et al.: Levamisole and Fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352-358. (Pubitemid 20042739)
2. O'Connell MJ, Mailliard JA, Kahn MJ, et al.: Controlled trial of fluorouracil and low-dose leucovorin given for six months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246-250. (Pubitemid 27020580)
3. Wolmark N, Rockette H, Fisher B, et al.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 1993, 11:1879-1887. (Pubitemid 23304611)
4. Wolmark N, Rockette H, Mamounas E, et al.: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17:3553-3559. (Pubitemid 29517927)
5. Gray R, Branwell J, McConkey C, et al.: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 2007, 370:2020-2029.
6. André T, Sargent D, Tabernero J, et al.: Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006, 13:887-898. (Pubitemid 43727375)
7. André T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351. (Pubitemid 38702845)
8. André T, Boni C, Navarro M, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II/III colon cancer: update from MOSAIC Trial. J Clin Oncol 2009 (in press). An update of the MOSAIC trial. Based on these results, the combination of oxaliplatin and 5-FU has become the standard adjuvant treatment for patients with stage III colon cancer.
9. Kuebler JP, Wieand HS, O'Connell MJ, et al.: Oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-2204. The results of this study confirm that an oxaliplatin-containing regimen in association with 5-FU/LV is the standard treatment for stage III colon cancer.
10. Petrelli Nj, Rustum YM, Bruckner H, Stablein D: The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma. Adv Exp Med Biol 1988, 244:143-155.
11. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947. (Pubitemid 30644117)
12. Kohne CH, Wils J, Lorenz M, et al.: Randomized phase III study of high dose 5-fluorouracil given as a weekly 24 hours infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003, 21:3721-3728. (Pubitemid 46606225)
13. de Gramont A: Association between 3-year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (rec) in patients receiving cytotoxic adjuvant therapy for colon cancer: findings from the 20,800 patient (pt) ACCENT dataset [abstract]. J Clin Oncol 2008, 26(May 20 Suppl):4007. This meta-analysis shows that the prolonged survival following recurrence, from the 13 months in the 5-FU era to more than 20 months, requires a longer follow-up to observe improvement of OS correlating to an advantage in 3-year disease-free survival.
14. Land SR, Kopec JA, Cecchini RS, et al.: Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP-07. J Clin Oncol 2007, 25:2205-2211. (Pubitemid 46954644)
15. Kuebler JP, Colangelo S, O'Connell MJ, et al.: Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer 2007, 110:1945-1950. (Pubitemid 350036852)
16. Sargent DJ, Wieand HS, Haller DG, et al.: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005, 23:8664-8670. (Pubitemid 46211509)
17. Sargent D, Sobrero A, Grothey A, et al.: Evidence for cure by adjuvant therapy in colon cancer: observation based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009, 27:872-877.
18. O'Connell MJ, Campbell ME, Goldberg RM, et al.: Survival following recurrence in stage II and III colon cancer: findings from ACCENT data set. J Clin Oncol 2008, 26:2336-2341.
19. André T, Quinaux F, Louvet C, et al.: Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007, 24:3732-3738. (Pubitemid 47372615)
20. Sharif S, O'Connell MJ, Yothers G, et al.: FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest 2008, 26:956-963.
21. Allegra CJ, Yothers G, O'Connell MJ, et al.: Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer [abstract]. Proc Am Soc Clin Oncol 2008, 26(May 20 Suppl):4006.
22. Taieb J, Puig PL, Bedenne L, et al.: Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. Expert Rev Anticancer Ther 2008, 8:183-189. (Pubitemid 351385908)
23. Benson AB 3rd: New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 2007, 13(22 Pt 2):6913s-6920s.
24. de Gramont A, Tournigand C, André T, et al.: Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 2007, 34(2 Suppl 1):S37-S40. (Pubitemid 46590359)